Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An invasive breast carcinoma characterized by the presence of a mesenchymal cellular component. The mesenchymal cellular component ranges from cartilaginous and osseous, to purely sarcomatous.
Biomarker and diagnostic research for mixed epithelial/mesenchymal metaplastic breast carcinoma has been reported in the published literature.
No clinical trials have been registered for mixed epithelial/mesenchymal metaplastic breast carcinoma.
11 publications have been identified in PubMed for mixed epithelial/mesenchymal metaplastic breast carcinoma. Research spans Case Report / Case Series (45%), Diagnostic / Biomarker (18%), and Review / Meta-Analysis (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 45% |
Data assembled from 2 of 12 sources · Last updated Sep 18, 2026, 1:37 AM UTC
Testing and diagnosis research |
2 |
18% |
Research summaries | 1 | 9% |
Clinical study results | 1 | 9% |
Laboratory research | 1 | 9% |
Disease patterns and progression | 1 | 9% |
Shashidhar Chittapragada V (2026). [PMID: 41891973](https://pubmed.ncbi.nlm.nih.gov/41891973/). *APMIS*. [Basic Science / Preclinical]
Mohamed BM (2026). [PMID: 41658824](https://pubmed.ncbi.nlm.nih.gov/41658824/). *Cureus*. [Case Report / Case Series]
Li Y (2025). [PMID: 40842546](https://pubmed.ncbi.nlm.nih.gov/40842546/). *Front Med (Lausanne)*. [Case Report / Case Series]
Dokania S (2025). [PMID: 41024247](https://pubmed.ncbi.nlm.nih.gov/41024247/). *J Med Case Rep*. [Case Report / Case Series]
Matusz-Fisher A (2025). [PMID: 40425384](https://pubmed.ncbi.nlm.nih.gov/40425384/). *Clin Breast Cancer*. [Clinical Trial Publication]
Zhang Q (2025). [PMID: 40081883](https://pubmed.ncbi.nlm.nih.gov/40081883/). *J Clin Pathol*. [Case Report / Case Series]
Yang E (2025). [PMID: 39628360](https://pubmed.ncbi.nlm.nih.gov/39628360/). *Histopathology*. [Epidemiology / Natural History]
Bahmad HF (2025). [PMID: 40563551](https://pubmed.ncbi.nlm.nih.gov/40563551/). *Cancers (Basel)*. [Review / Meta-Analysis]
Zhang F (2025). [PMID: 41026783](https://pubmed.ncbi.nlm.nih.gov/41026783/). *PLoS One*. [Diagnostic / Biomarker]
Tomey V (2024). [PMID: 38948622](https://pubmed.ncbi.nlm.nih.gov/38948622/). *J Family Med Prim Care*. [Case Report / Case Series]
AI-curated news mentioning mixed epithelial/mesenchymal metaplastic breast carcinoma
Updated Aug 24, 2026
A recent study provides insights into metaplastic breast cancer through a single-center retrospective analysis. The findings contribute to the understanding of this rare subtype of breast cancer, although specific data points were not detailed.
A case report and literature review highlight the multimodal imaging evaluation of early-stage metaplastic breast carcinoma with heterologous mesenchymal differentiation. This study contributes to the understanding of imaging techniques in rare breast cancer subtypes.
A case report highlights the long-term response to pembrolizumab in a patient with metastatic metaplastic breast carcinoma. This finding may inform future treatment strategies for this rare breast cancer subtype.